



On behalf of Allergan, an AbbVie Company, we are delighted to invite you to the second webinar in The Eye Series.

The 'Real World Management of Retinal Disease' meeting takes place on

Wednesday 28th April 2021, 7-8pm via the ON24 platform

To register for this webinar please click [here](#).

The webinar will include presentations from:



Professor Laurent Kodjikian is Professor of Ophthalmology and Chair of the University of Lyon, France, and Associate Chair of the Department of Ophthalmology at Croix-Rousse University Hospital in Lyon.

Prof Kodjikian will discuss Real World Evidence in the management of patients with DMO and RVO.



Dr Fiona Harney, Lecturer in Ophthalmology and Consultant Ophthalmologist, UCHG, who will discuss the management of patients with DMO and RVO in UCHG.



Mr John Doris, Consultant Ophthalmologist, UHW, who will discuss The Waterford audit results and the management of patients with DMO and RVO in UHW.

CPD from the ICO has been applied for.

Ozurdex Summary of Product Characteristics is available on www.medicines.ie

For adverse events please contact UK_medinfo@allergan.com or **01628 494026**

For further information on this event, please contact your OZURDEX® representative below.

AbbVie Limited
14 Riverwalk
Citywest Business Park
Dublin 24
D24 XN32

You have indicated that you would like to receive promotional emails such as this in the past. If you no longer want to receive emails with promotional content from Allergan please notify sender by return email.

This e-mail, including any attachments, is meant only for the intended recipient and may be a confidential communication or a communication privileged by law. If you received this e-mail in error, any review, use, dissemination, distribution, or copying of this e-mail is strictly prohibited. Please notify the sender immediately of the error by return e-mail and please delete this message from your system. Thank you in advance for your cooperation.

This is a promotional meeting organised and funded by Allergan, an AbbVie Company.

IE-ABBV-210083 Date of preparation April 2021